Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best healthcare stocks under $50 to invest in. Barclays maintained an Overweight rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) on January 30, adjusting the price target on the stock to $38 from $35. It told investors that it updated the company’s model after the fiscal Q4 report, and expressed confidence in the shares at these levels.

In addition to Barclays, Scotiabank also raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $40 from $35 on January 29 and maintained an Outperform rating on the shares. The firm expressed optimism for the stock after the fiscal Q4 results, and told investors in a research note that it upgraded the price target because of the company’s execution continually surpassing expectations.

The rating updates came after Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced on January 28 that it delivered three consecutive years of growth, with 2025 revenues of $17.3 billion, reflecting a 4% year-over-year growth in U.S. dollars, or 3% in local currency terms, compared to 2024. Revenues rose 5% YoY in local currency, excluding Japan BV. The company’s key innovation brands continued to drive growth, with 2025 revenues exceeding $3 billion, up 35% year-over-year in local currency. Fiscal Q4 2025 marked the first quarter in which these brands collectively delivered ~$1 billion of revenues.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.